![](https://hayatbiotech.com/wp-content/themes/hayat-biotech/img/top-block-1.png)
![Immunogenicity and safety of NVSI-06-07](https://hayatbiotech.com/wp-content/uploads/2022/05/pexels-kindel-media-8325966.jpg)
Immunogenicity and safety of NVSI-06-07 by Dr. Nawal AlKaabi
![](https://hayatbiotech.com/wp-content/uploads/2022/05/DrNawal.png)
The epidemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has stimulated global efforts to develop safe and effective vaccines against the rapid spread of the virus.
So far, great progress has been achieved, and a total of ten vaccines have been approved by the world health organization (WHO) for emergency use, including three inactivated, two mRNA-based, three viral vector-based and two recombinant nanoparticle protein-based vaccines.